Skip to main content
. 2017 Nov 20;12(11):e0188454. doi: 10.1371/journal.pone.0188454

Fig 1. Comparison of BTM and BMD between patients with ACPA-positive RA and those with ACPA-negative RA before and after tocilizumab treatment.

Fig 1

(A) osteocalcin, (B) P1NP, (C) CTX, (D) lumbar spine BMD, (E) right femoral neck BMD, and (F) left femoral neck BMD Error bars: mean ± standard error, *: p value < 0.05 by the Wilcoxon signed rank test. ACPA: anticitrullinated protein antibody; BMD: bone mineral density; BTM: bone turnover markers; CTX: C-terminal cross-linking telopeptide of type I collagen; P1NP: N-terminal propeptide of type I collagen; RA: rheumatoid arthritis.